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Background: Bleeding activates platelets that can bind tumour cells, potentially promoting metastatic
growth in patients with cancer. This study investigated whether reoperation for postoperative bleeding
is associated with breast cancer recurrence.
Methods: Using the Danish Breast Cancer Group database and the Danish National Patient Register
(DNPR), a cohort of women with incident stage I–III breast cancer, who underwent breast-conserving
surgery or mastectomy during 1996–2008 was identified. Information on reoperation for bleeding within
14days of the primary surgery was retrieved from the DNPR. Follow-up began 14days after primary
surgery and continued until breast cancer recurrence, death, emigration, 10 years of follow-up, or
1 January 2013. Incidence rates of breast cancer recurrence were calculated and Cox regression models
were used to quantify the association between reoperation and recurrence, adjusting for potential
confounders. Crude and adjusted hazard ratios according to site of recurrence were calculated.
Results: Among 30711 patients (205 926 person-years of follow-up), 767 patients had at least one
reoperation within 14days of primary surgery, and 4769 patients developed breast cancer recurrence.
Median follow-up was 7⋅0 years. The incidence of recurrence was 24⋅0 (95 per cent c.i. 20⋅2 to 28⋅6)
per 1000 person-years for reoperated patients and 23⋅1 (22⋅5 to 23⋅8) per 1000 person-years for
non-reoperated patients. The overall adjusted hazard ratio was 1⋅06 (95 per cent c.i. 0⋅89 to 1⋅26). The
estimates did not vary by site of breast cancer recurrence.
Conclusion: In this large cohort study, there was no evidence of an association between reoperation for
bleeding and breast cancer recurrence.
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Introduction
Breast cancer is the most common cancer among women,
with about 1⋅67 million new patients diagnosed in 20121.
With 522 000 annual breast cancer-related deaths esti-
mated worldwide, it is the leading cause of cancer-related
death in women in developing countries, and second only
to lung cancer in more developed regions1.
Surgery, either breast-conserving surgery (BCS) or
mastectomy, is the primary treatment for breast cancer.
Despite its therapeutic intent, surgery causes physiological
stress, which, along with anaesthesia2, can lead to transient
immunosuppression during the perioperative period3.
Such transient immunosuppression may lead to poorer
immune detection of cancer cells3.
Postoperative bleeding requiring reoperation occurs in
up to 4 per cent of women undergoing surgery for breast
cancer4. Depending on the age of the patient and extent of
primary surgery (mastectomy versus BCS)5, the use of cer-
tain prescription drugs (such as selective serotonin reuptake
inhibitors (SSRIs) or glucocorticoids) increases the risk
of postoperative bleeding requiring reoperation5,6. How-
ever, there is no evidence of an effect of SSRIs and glu-
cocorticoid use on breast cancer recurrence5–7. Bleeding
activates platelets, which can bind tumour cells, promot-
ing immune evasion, angiogenesis, tumour cell survival
and metastatic growth8. Cancer is associated with a hyper-
coagulable state9,10, with heightened platelet activation
and a correlation with poor prognosis11. Thus, patients
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with breast cancer who develop postoperative bleeding
requiring reoperation may be at increased risk of breast
cancer recurrence.
This cohort study was conducted to investigate the
association between bleeding occurring within 14 days of
primary breast cancer surgery and the rate of recurrence
among patients with breast cancer in Denmark.
Methods
This study was approved by the Danish Data Protec-
tion Agency (Record 2007-58-0010), theDanishMedicines
Agency and the Danish Breast Cancer Group (DBCG).
The study is based on routinely collected registry data and
according to Danish regulations does therefore not require
separate ethical approval.
Setting
This was a nationwide cohort study using Danish
population-based registries. Denmark’s national health ser-
vice provides tax-supported healthcare to Danish citizens
and permanent residents, including unrestricted access
to hospital care and partial reimbursement for prescribed
medications12,13. At birth or immigration, each person is
assigned a unique civil personal registration number (CPR
number) that allows unambiguous individual-level linkage
among all Danish administrative and population-based
registries, including medical registries13.
Source population and data collection
The registry of the DBCG14,15 and the Danish National
Patient Register (DNPR) was used to identify all women
with an incident diagnosis of operable stage I–III breast
cancer who underwent BCS or mastectomy between 1996
and 2008. To ensure correct retrieval of the exposure,
defined as reoperation for postoperative bleeding within
14 days following primary breast cancer-directed surgery,
patients were considered eligible for inclusion in the study
if there was a difference of 1 day or less between the
recorded date of primary surgery in the DNPR andDBCG
database.
The DBCG has registered almost all women with inva-
sive breast cancer in Denmark since 197716. Data on
tumour and patient characteristics are collected prospec-
tively by treating physicians. The completeness of registra-
tion is approximately 95 per cent16. Patients registered in
the DBCG database undergo regular follow-up examina-
tions aimed at detecting recurrent disease17. The follow-
ing information was obtained from the DBCG database:
age and menopausal status at diagnosis, type of surgery,
WHOhistological tumour type and grade, lymph node sta-
tus, tumour size, oestrogen receptor (ER) status, receipt
of adjuvant chemotherapy, endocrine therapy (ET) and/or
radiation therapy, and date and site of recurrence.
The DNPR has collected data on all non-psychiatric
hospital admissions since 1977, and on all outpatient
and emergency contacts since 1995. Data in the DNPR
include the CPR number, one primary diagnosis, and
one or more secondary diagnoses classified according
to the ICD, as well as data on diagnostic and surgical
procedures18.
The DNPR was used to retrieve information on re-
operation for bleeding after surgery (Table S1, supporting
information) within 14 days following primary surgery for
breast cancer. Information was retrieved from the DNPR
on potentially confounding other diseases (co-morbidity)
registered up to 10 years before the breast cancer diagnosis.
These were summarized using the Charlson Co-morbidity
Index (CCI)19, modified to exclude breast cancer diag-
noses. Co-morbidity prevalent on the date of breast
cancer surgery was studied in order to detect diseases
that could potentially confound or modify the associ-
ation between bleeding after surgery and a later breast
cancer recurrence20–23. These included: diabetes, liver dis-
ease, chronic pulmonary disease, peripheral and cerebral
vascular disease, any other cancer, myocardial infarc-
tion and congestive heart failure (Table S2, supporting
information). Information on death and emigration was
retrieved from the Civil Registration System (CRS).
The CRS, established in 1968, contains information
on the vital status of all Danish citizens; it is updated
daily12.
The National Prescription Registry has automati-
cally recorded detailed information on all prescriptions
redeemed at Danish community pharmacies since 199524.
Information is transferred electronically into the registry
at the time of prescription redemption, so the validity
of the registry is extremely high25. The registry contains
detailed information on dispensed prescriptions, including
full Anatomical Therapeutic Chemical codes, and date
and quantity dispensed24. Data on drugs that potentially
confound the association between bleeding and recur-
rence were retrieved, including simvastatin and aspirin,
which may modify breast cancer prognosis26,27, and hor-
mone replacement therapy (HRT) (Table S3, supporting
information).
Variables analysed
Age at diagnosis was categorized into decades. Histolog-
ical grade was defined as low, moderate or high, based
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Table 1 Baseline characteristics of 30 711 patients diagnosed with stage I–III breast cancer in Denmark, 1996–2008, according to
reoperation for postoperative bleeding
All patients Recurrence Total person-years
Reoperation
(n=767)
No reoperation
(n=29944)
Reoperation
(n=126)
No reoperation
(n=4643) Reoperation No reoperation
Overall 5241 200 685
Age at diagnosis (years)
≤29 0 (0) 98 (0⋅3) 0 (0) 32 (0⋅7) 0 578
30–39 30 (3⋅9) 1357 (4⋅5) 8 (6⋅3) 311 (6⋅7) 217 9073
40–49 112 (14⋅6) 5070 (16⋅9) 20 (15⋅9) 838 (18⋅0) 850 36 701
50–59 237 (30⋅9) 8962 (29⋅9) 43 (34⋅1) 1455 (31⋅3) 1683 63 381
60–69 230 (30⋅0) 9258 (30⋅9) 31 (24⋅6) 1357 (29⋅2) 1550 61 232
70–79 131 (17⋅1) 4254 (14⋅2) 23 (18⋅3) 576 (12⋅4) 816 25 602
≥80 27 (3⋅5) 945 (3⋅2) 1 (0⋅8) 74 (1⋅6) 124 4118
Menopausal status at diagnosis
Premenopausal 191 (24⋅9) 8226 (27⋅5) 36 (28⋅6) 1380 (29⋅7) 1411 59 317
Postmenopausal 576 (75⋅1) 21 704 (72⋅5) 90 (71⋅4) 3262 (70⋅3) 3830 141 296
Missing 0 (0) 14 (0⋅0) 0 (0) 1 (0⋅0) 0 72
Charlson Co-morbidity Index score
0 589 (76⋅8) 23 913 (79⋅9) 110 (87⋅3) 3879 (83⋅5) 4152 165 150
1 107 (14⋅0) 3357 (11⋅2) 12 (9⋅5) 446 (9⋅6) 701 20 666
2 47 (6⋅1) 1683 (5⋅6) 2 (1⋅6) 209 (4⋅5) 265 9947
≥3 24 (3⋅1) 991 (3⋅3) 2 (1⋅6) 109 (2⋅3) 123 4922
Specific co-morbidities
Myocardial infarction 15 (2⋅0) 356 (1⋅2) 1 (0⋅8) 42 (0⋅9) 79 1987
Congestive heart failure 18 (2⋅3) 385 (1⋅3) 1 (0⋅8) 35 (0⋅8) 74 1937
Vascular disease 21 (2⋅7) 518 (1⋅7) 1 (0⋅8) 68 (1⋅5) 127 2818
Cerebrovascular disease 40 (5⋅2) 1013 (3⋅4) 1 (0⋅8) 114 (2⋅5) 274 5597
Chronic pulmonary disease 39 (5⋅1) 1459 (4⋅9) 7 (5⋅6) 174 (3⋅7) 211 8467
Diabetes types 1 and 2 20 (2⋅6) 811 (2⋅7) 1 (0⋅8) 114 (2⋅5) 112 4491
Diabetes with organ damage 8 (1⋅0) 346 (1⋅2) 1 (0⋅8) 41 (0⋅9) 41 1824
Liver disease 10 (1⋅3) 250 (0⋅8) 1 (0⋅8) 33 (0⋅7) 29 1296
Any other cancer 24 (3⋅1) 1286 (4⋅3) 1 (0⋅8) 154 (3⋅3) 152 7360
Values in parentheses are percentages.
on WHO histological tumour type28. Stage was classified
as I, II or III according to the UICC classification (6th
edition)29. Lymph node status was defined according to
number of involved nodes (0, 1–3, 4 or more). Tumour size
was categorized as 20mm or less, or over 20mm. ER and
adjuvant ET were summarized as: ER+/ET+, ER–/ET–,
ER+/ET– or ER−/ET+. Surgery type was either mastec-
tomy or BCS. Treatment with adjuvant chemotherapy was
categorized dichotomously. Menopausal status at diagno-
sis was either premenopausal or postmenopausal, classified
according to the DBCG.
Simvastatin and aspirin use were modelled as time-
varying co-variables. Longitudinal prescription data were
used to define time-updated exposure to these drugs. For
each prescription, prescription duration was calculated as
pack size (number of pills per pack) multiplied by the num-
ber of packages redeemed, assuming that a single pill was
taken each day. In defining continuous use, a gap of 30 days
was allowed from the end of one prescription (prescription
start date+ prescription duration) until the start of a new
prescription. If a new prescription was redeemed within
this window, then exposure was assumed to continue; if
not, the patient was considered to have stopped the drug
at the end of the 30-day grace period. The patient could
later restart if there were further prescriptions. Finally, the
resulting time-updated current medical exposure variable
lagged by 1 year to allow the effect of the drug to accrue, as
any effects on cancer are likely to be delayed, and to min-
imize confounding by indication. HRT was recorded as a
baseline co-variable among women with at least 1 year of
prescription history.
Breast cancer recurrence was defined according to the
DBCG as any local, regional or distant recurrence, or
cancer of the contralateral breast up to 10 years after the
primary diagnosis14.
Follow-up began 14 days after primary breast cancer
surgery (registered in the DNPR) and continued until
breast cancer recurrence, death, emigration, 10 years of
follow-up or 1 January 2013 (end of the study period),
whichever came first.
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Table 2 Baseline tumour characteristics and treatments of 30 711 patients diagnosed with stage I–III breast cancer in Denmark,
1996–2008, according to reoperation for postoperative bleeding
All patients Recurrence Total person-years
Reoperation
(n= 767)
No reoperation
(n=29944)
Reoperation
(n=126)
No reoperation
(n=4643) Reoperation No reoperation
Overall 5241 200 685
UICC stage
I 284 (37⋅0) 10 852 (36⋅2) 36 (28⋅6) 1157 (24⋅9) 2095 78 669
II 367 (47⋅8) 13 465 (45⋅0) 52 (41⋅3) 1844 (39⋅7) 2539 92 554
III 107 (14⋅0) 5406 (18⋅1) 38 (30⋅2) 1620 (34⋅9) 550 28 262
Missing 9 (1⋅2) 221 (0⋅7) 0 (0) 22 (0⋅5) 57 1200
Tumour size (mm)
≤20 438 (57⋅1) 17 190 (57⋅4) 57 (45⋅2) 2026 (43⋅6) 3160 121 891
>20 321 (41⋅9) 12 544 (41⋅9) 67 (53⋅2) 2574 (55⋅4) 2021 77 267
Missing 8 (1⋅0) 210 (0⋅7) 2 (1⋅6) 43 (0⋅9) 60 1528
Lymph node status
Negative 405 (52⋅8) 15 522 (51⋅8) 51 (40⋅5) 1807 (38⋅9) 2963 111 142
1–3 postive nodes 255 (33⋅2) 9147 (30⋅5) 38 (30⋅2) 1266 (27⋅3) 1731 62 306
≥4 positive nodes 104 (13⋅6) 5151 (17⋅2) 37 (29⋅4) 1563 (33⋅7) 533 26 735
Missing 3 (0⋅4) 124 (0⋅4) 0 (0) 7 (0⋅2) 14 502
Histological grade
Low 621 (81⋅0) 24 522 (81⋅9) 105 (83⋅3) 3846 (82⋅8) 4218 163 024
Moderate 100 (13⋅0) 3301 (11⋅0) 11 (8⋅7) 548 (11⋅8) 714 22 769
High 44 (5⋅7) 1992 (6⋅7) 9 (7⋅1) 222 (4⋅8) 297 13 972
Missing 2 (0⋅3) 129 (0⋅4) 1 (0⋅8) 27 (0⋅6) 11 920
ER/adjuvant ET status
ER–/ET– 134 (17⋅5) 5818 (19⋅4) 21 (16⋅7) 1174 (25⋅3) 892 35 750
ER+/ET– 184 (24⋅0) 7143 (23⋅9) 25 (19⋅8) 1087 (23⋅4) 1399 52 922
ER+/ET+ 420 (54⋅8) 15 985 (53⋅4) 76 (60⋅3) 2177 (46⋅9) 2736 104 739
ER–/ET+ 5 (0⋅7) 181 (0⋅6) 1 (0⋅8) 27 (0⋅6) 39 1330
Unknown 24 (3⋅1) 817 (2⋅7) 3 (2⋅4) 178 (3⋅8) 174 5944
Type of primary surgery
Mastectomy 373 (48⋅6) 10 838 (36⋅2) 65 (51⋅6) 1867 (40⋅2) 2527 74 573
Mastectomy+RT 159 (20⋅7) 6486 (21⋅7) 34 (27⋅0) 1445 (31⋅1) 1074 41 563
BCS+RT 235 (30⋅6) 12 620 (42⋅1) 27 (21⋅4) 1331 (28⋅7) 1639 84 550
Adjuvant chemotherapy
Yes 220 (28⋅7) 10 075 (33⋅6) 33 (26⋅2) 1628 (35⋅1) 1509 65 009
No 547 (71⋅3) 19 869 (66⋅4) 93 (73⋅8) 3015 (64⋅9) 3732 135 676
HRT before diagnosis
Yes 316 (41⋅2) 12 452 (41⋅6) 37 (29⋅4) 1634 (35⋅2) 2220 83 790
No 451 (58⋅8) 17 492 (58⋅4) 89 (70⋅6) 3009 (64⋅8) 3021 116 896
Drugs taken during study period
Simvastatin 148 (19⋅3) 6286 (21⋅0) 7 (5⋅6) 349 (7⋅5) 538 22 527
Aspirin (high and low doses) 190 (24⋅8) 6233 (20⋅8) 15 (11⋅9) 556 (12⋅0) 532 17 ,613
Values in parentheses are percentages. ER, oestrogen receptor; ET, endocrine therapy; RT, radiotherapy; BCS, breast-conserving surgery; HRT,
hormone replacement therapy.
Statistical analysis
The proportion of patients with breast cancer who did
or did not undergo reoperation for bleeding after surgery
was calculated, by patient, tumour and treatment char-
acteristics. Incidence rates (IRs) of recurrence per 1000
person-years were calculated, and the 5- and 10-year cumu-
lative incidence of recurrence was estimated according to
whether reoperation for bleeding after primary surgery
had been undertaken. IRs were also categorized by time
after surgery; recurrences developing within 2 years repre-
sented very early recurrence, those diagnosed at 2–5 years
comprised early recurrence, and recurrences detected after
5 years represented late recurrence30.
The proportion of patients with breast cancer receiving
mastectomy and BCS over time was calculated, as was the
proportion needing a further operation over time.
Cox regression models with time from start of follow-up
as the underlying time scale were used to compute
crude and adjusted hazard ratios (HRs) for recurrence
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Table 3 Incidence rates and hazard ratios for breast cancer recurrence, according to reoperation for postoperative bleeding, among
30 711 women diagnosed with stage I–III breast cancer in Denmark, 1996–2008 with follow-up to 31 December 2012
No. of
recurrences
Person-
years
Crude incidence rate
(per 100 000 person-years)
Unadjusted
hazard ratio
Adjusted
hazard ratio*
Overall (reoperation within 14days)†
No reoperation 4643 200685 23⋅1 (22⋅5, 23⋅8) 1⋅00 (reference) 1⋅00 (reference)
Reoperation 126 5241 24⋅0 (20⋅2, 28⋅6) 1⋅05 (0⋅88, 1⋅25) 1⋅06 (0⋅89, 1⋅26)
Reoperation within 7 days†
No reoperation 4650 201520 23⋅1 (22⋅4, 23⋅7) 1⋅00 (reference) 1⋅00 (reference)
Reoperation 121 4995 24⋅2 (20⋅3, 28⋅9) 1⋅06 (0⋅88, 1⋅27) 1⋅08 (0⋅91, 1⋅30)
Values in parentheses are 95 per cent confidence intervals. Hazard ratios with 95 per cent confidence intervals are shown. *Hazard ratios were adjusted for
age (as a categorical variable), menopausal status at diagnosis (premenopausal, postmenopausal), lymph node status (negative, 1–3 positive nodes, at least
4 positive nodes), tumour size (20mm or smaller, larger than 20mm), histological grade (low, moderate, high), type of surgery, oestrogen receptor (ER)
status and receipt of endocrine therapy (ET) (ER+/ET–, ER+/ET+, ER–/ET–, ER–/ET+), receipt of chemotherapy (yes, no), simvastatin use and
aspirin use (both as time-varying co-variables lagging by 1 year), co-morbidity, and receipt of hormone replacement therapy before diagnosis (yes, no).
†The total number of patients with recurrence is not identical here because two patients died or developed a recurrence before the start of follow-up on
day 14.
Overall
Bone
Contralateral breast
Ipsilateral breast
Lymph node
Lungs and pleura
Liver
CNS
All other sites
0 1 2
1·06 (0·89, 1·26)
0·81 (0·56, 1·15)
1·22 (0·82, 1·82)
1·20 (0·82, 1·79)
1·24 (0·82, 1·86)
0·88 (0·55, 1·40)
1·03 (0·64, 1·67)
1·28 (0·53, 3·13)
0·95 (0·49, 1·85)
Fig. 1 Forest plot showing associations between reoperation for postoperative bleeding and anatomical site of recurrence. Hazard ratios
with 95 per cent confidence intervals are shown. Hazard ratios were adjusted for age (as a categorical variable), menopausal status at
diagnosis (premenopausal, postmenopausal), lymph node status (negative, 1–3 positive nodes, at least 4 positive nodes), tumour size
(20mm or smaller, larger than 20mm), histological grade (low, moderate, high), type of surgery, oestrogen receptor (ER) status and
receipt of endocrine therapy (ET) (ER+/ET–, ER+/ET+, ER–/ET–, ER–/ET+), receipt of chemotherapy (yes, no), simvastatin use
and aspirin use (both as time-varying co-variables lagging by 1 year), co-morbidity, and receipt of hormone replacement therapy before
diagnosis (yes, no). CNS, central nervous system
and associated 95 per cent confidence intervals for
reoperation for postoperative bleeding. To model the
cause-specific hazard, patients who died without a breast
cancer recurrence were censored at the date of death.
The adjusted model included the following potential
confounders: age group at diagnosis, menopausal status,
receipt of chemotherapy, lymph node status, tumour size,
tumour grade, type of primary surgery, ER/ET status,
co-morbidity, baseline HRT, and simvastatin and aspirin
use after diagnosis (coded as time-varying co-variables
lagging by 1 year). The analyses were stratified by age,
receipt of chemotherapy, UICC stage and type of primary
surgery. Crude and adjusted HRs according to site of
recurrence were calculated.
The following sensitivity analyses were conducted:
changing the 14-day window for reoperation and start
of follow-up to 7 days after primary surgery; changing
the inclusion criteria from no more than 1 day differ-
ence between the recorded date of primary surgery
in the DNPR and the DBCG database to no more
than 14 days and no more than 31 days; changing the
study population to include only patients with stage I
and II disease at diagnosis; and excluding patients with
previous cancers.
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No
Yes
Chemotherapy
Overall
Age (years)
< 50
50–59
60–69
≥ 70
UICC stage
I
II
III
Type of primary therapy
Mastectomy no RT
Mastectomy + RT
BCS + RT
0 1 2
1·11 (0·90, 1·36)
1·01 (0·71, 1·42)
1·09 (0·74, 1·60)
1·04 (0·74, 1·47)
1·10 (0·86, 1·41)
1·16 (0·84, 1·61)
1·03 (0·78, 1·35)
1·14 (0·82, 1·59)
1·13 (0·75, 1·70)
0·90 (0·63, 1·29)
1·14 (0·84, 1·53)
1·20 (0·82, 1·74)
1·06 (0·89, 1·26)
Fig. 2 Forest plot showing associations between reoperation for postoperative bleeding and rate of breast cancer recurrence, stratified by
age, UICC stage and type of primary therapy. Hazard ratios with 95 per cent confidence intervals are shown. Hazard ratios were
adjusted for age (as a categorical variable), menopausal status at diagnosis (premenopausal, postmenopausal), lymph node status
(negative, 1–3 positive nodes, at least 4 positive nodes), tumour size (20mm or smaller, larger than 20mm), histological grade (low,
moderate, high), type of surgery, oestrogen receptor (ER) status and receipt of endocrine therapy (ET) (ER+/ET–, ER+/ET+,
ER–/ET–, ER–/ET+), receipt of chemotherapy (yes, no), simvastatin use and aspirin use (both as time-varying co-variables lagging by
1 year), co-morbidity, and receipt of hormone replacement therapy before diagnosis (yes, no). RT, radiotherapy; BCS,
breast-conserving surgery
Analyses were performed using Stata® version 13 (Stata-
Corp, College Station, Texas, USA).
Results
A total of 33 162 patients with breast cancer who underwent
BCS or mastectomy between 1996 and 2008 were identi-
fied. The cohort consisted of 30 711 women after exclusion
of 2425 women with more than 1 day difference in the date
of surgery, or inconsistency in type of surgery, between the
DNPR and the DBCG database, and 26 women who died
or had an event registered before the start of follow-up
(within 14 days after primary breast cancer surgery). The
proportion of patients treated with BCS versusmastectomy
increased in recent years accompanied by a decline in the
rate of reoperation. Median follow-up was 7⋅0 years.
Reoperation after surgery
Overall, 767 patients (2⋅5 per cent) had at least one reopera-
tion within 14 days of the primary surgery. Compared with
women who were not reoperated, a higher proportion of
patients who underwent reoperation were postmenopausal
(75⋅1 versus 72⋅5 per cent), and had co-morbid disease
(CCI score of at least 1: 23⋅2 versus 20⋅1 per cent), a his-
tory of cerebrovascular disease (5⋅2 versus 3⋅4 per cent)
and moderate-grade tumours (13⋅0 versus 11⋅0 per cent)
(Tables 1 and 2). Reoperated patients were more likely
to have undergone mastectomy than BCS as primary
surgery (69⋅3 versus 57⋅9 per cent) and less likely to receive
chemotherapy (28⋅7 versus 33⋅6 per cent). A higher propor-
tion of patients without reoperation had stage III cancer
(18⋅1 versus 14⋅0 per cent). Overall, 21⋅0 per cent of women
in the breast cancer cohort had been prescribed aspirin or
simvastatin during follow-up, and 41⋅6 per cent had been
prescribed HRT before the breast cancer diagnosis. Re-
operated patients were more likely to be concurrent aspirin
users.
Recurrence after reoperation for bleeding
Overall, 4769 patients developed breast cancer recurrence
during follow-up. The IR of recurrence was 24⋅0 (95 per
cent c.i. 20⋅2 to 28⋅6) and 23⋅1 (22⋅5 to 23⋅8) per 1000
person-years for reoperated and non-reoperated patients
respectively (Table 3). Regardless of reoperation status, the
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incidence rate was higher in the first 2 years after surgery,
followed by a decrease (Table S4, supporting information).
The 1-year IR of recurrence was 29⋅1 (13⋅1 to 44⋅1) and
21⋅3 (19⋅7 to 23⋅1) per 1000 person-years for reoper-
ated and non-reoperated patients respectively. The IR of
recurrence in the second year after primary surgery was
40⋅7 (28⋅3 to 58⋅6) per 1000 person-years for reoperated
patients and 34⋅7 (32⋅6 to 36⋅9) per 1000 person-years for
non-reoperated patients. After 5 years of follow-up, the IRs
for patients who did and did not undergo reoperation were
similar: 27⋅7 (22⋅6 to 33⋅9) and 26⋅9 (26⋅1 to 27⋅8) per 1000
person-years respectively. The 5-year cumulative incidence
of recurrence was 12⋅8 and 12⋅5 per cent for patients with
and without reoperation respectively; the 10-year cumula-
tive incidence of recurrence was 19⋅9 per cent for reoper-
ated patients and 18⋅9 per cent for non-reoperated patients
(Table S5, supporting information).
Among 767 patients who underwent reoperation, there
were 126 recurrences in 5241 person-years of follow-up.
Among 29 944 women who did not undergo reoperation,
there were 4643 recurrences in 200 685 person-years of
follow-up. After adjusting for potential confounders, no
association between bleeding after surgery and breast can-
cer recurrence was observed (adjusted HR 1⋅06, 95 per
cent c.i. 0⋅89 to 1⋅26), regardless of time interval of expo-
sure (7 or 14 days after primary operation) (Table 3). This
lack of association did not change in sensitivity analyses
in which the study population included only patients with
stage I and II disease at diagnosis, patients with previ-
ous cancers were excluded, or patients with a difference in
surgery date between theDNPR andDBCGdatabase of no
more than 14 days and no more than 31 days were included
(Table S6, supporting information). The estimates did not
vary by site of breast cancer recurrence (Fig. 1), and there
was no evidence of effect modification in models stratified
by age, tumour stage, type of primary surgery or receipt of
chemotherapy (Fig. 2).
Discussion
Previous research in Danish patients reported an associ-
ation between re-excision (owing to insufficient surgical
margins within 2months of BCS) and increased risk of
ipsilateral breast tumour recurrence31. This finding was,
however, largely explained by residual disease31. The
hypothesis for the present study was that patients who
undergo reoperation for postoperative bleeding would be
at increased risk of ipsilateral breast tumour recurrence.
No evidence was found of an association between re-
operation for bleeding after surgery and later breast cancer
recurrence, regardless of time interval of exposure (7 or
14 days after the primary operation). Furthermore, the
estimates did not vary in analyses stratified by clinical
factors, the extent of primary surgery, or by site of breast
cancer recurrence. A slight increase in early recurrence
among reoperated patients was observed, but the estimates
are imprecise.
Research suggests that mastectomy is associated with a
higher risk of intraoperative bleeding and postoperative
complications than BCS32–34. However, mastectomy
alone and BCS combined with radiotherapy have equal
efficacy in terms of preventing breast cancer recurrence35.
Results from the present study show that the asso-
ciation of postoperative bleeding with breast cancer
recurrence is not modified by the extent of primary
surgery.
The associations observed for reoperation and breast
cancer recurrence are not in line with those seen in
patients undergoing surgery for gastrointestinal cancers.
For example, intraoperative blood loss associated with
surgery for upper gastrointestinal tract tumours decreases
the activity of natural killer cells, which are the body’s pri-
mary defence mechanism against cancer36. Research sug-
gests that blood loss during surgery, regardless of whether
blood transfusion is given, is a risk factor for peritoneal
recurrence after curative resection of gastric cancer37. The
mechanisms for the lack of concordance between these
findings and those of the present study on breast cancer are
unclear. Blood loss that can be controlled by further opera-
tion could be less extensive than blood loss that is sufficient
to warrant a blood transfusion.
The main strengths of this study include its large size and
population-based nationwide designwithin a setting of uni-
versal tax-supported healthcare. The prospective data col-
lection reduced the potential for selection bias and ensured
virtually complete follow-up. Furthermore, comprehensive
data on potential confounders, including prescription drug
data, were available. The crude estimates were quite similar
to the adjusted estimates, and thus there was little evidence
of confounding. It is also a strength that reoperation for
bleeding after surgery has a surgical procedure code and is
therefore well recorded in the database. Although the posi-
tive predictive value of this specific procedure code has not
been assessed in the DNPR, it is expected to be high, as
hospitals in Denmark are reimbursed only after registra-
tion of surgical procedures. It is nevertheless possible that
other operative procedures could be misclassified as reop-
eration owing to postoperative bleeding. These include the
codes for reoperation for postoperative infection or reoper-
ation owing to other causes, which may include insufficient
surgical margins (Table S1, supporting information). How-
ever, the latter misclassification is likely to bias the present
© 2017 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2017; 104: 1665–1674
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findings away from the lack of effect of reoperation as resid-
ual disease is well known to be associated with recurrence31.
The impact of postoperative infection on later breast can-
cer recurrence remains unclear.
Earlier studies38,39 used blood transfusion as a proxy for
perioperative bleeding. However, in the case of breast can-
cer surgery, perioperative bleeding does not always result
in blood transfusion. Furthermore, patients who receive
blood transfusions are often sicker, with disseminated can-
cer, and more extensive co-morbidity.
The present study has some limitations. Information was
missing on the extent of postoperative bleeding, in terms
of actual blood loss. There was no information available
on surgical complications that may have precipitated such
bleeding. Another concern is the risk of selection bias due
to exclusion of patients; however, the excluded patients
were younger, had less advanced disease stages at diag-
nosis, and were less likely to receive mastectomy and ET
(Table S7, supporting information). The sensitivity analy-
ses also showed that the inclusion of these patients did not
change the present findings (Table S6, supporting informa-
tion). No information was available on the type of axillary
surgery. However, from 2001 to 2006 the sentinel node
technique was gradually introduced in Denmark40. During
the study interval, all women with metastasis of any size
in the axilla were offered axillary clearance level I+ II as
standard care.
Aspirin has been shown to decrease the risk of breast
cancer mortality in some26, but not all41,42 studies, whereas
simvastatin has been consistently associated with a
decreased risk of breast cancer recurrence/mortality43.
Information on prescribed aspirin was available, but it was
not possible to account for aspirin bought over the counter.
Aspirin formulations are available over the counter in Den-
mark but, if prescribed, almost exclusively done so in low
doses for cardiovascular prevention. Over-the-counter
aspirin is available only in small packs, and supplies for
regular use are usually prescribed by physicians and
reimbursable via the Danish National Health Insurance
System. The proportions of total sales of low-dose aspirin
dispensed by prescription, and thus captured in prescrip-
tion registries, is high (92 per cent in 2012)44, so residual
confounding regarding aspirin is expected to be a minor
issue. No information on prescription compliance was
available. In Denmark, patients pay part of the cost of
redeemed prescriptions, so the estimates are likely to
reflect actual use. Adjustment for prescribed aspirin and
simvastatin did not change the findings. Finally, despite
the large study size, reoperation for postoperative bleeding
was relatively rare in this population and thus the precision
of some of the estimates is low.
The findings of the present study have important clin-
ical implications, and provide reassurance to patients and
physicians that reoperation for postoperative bleeding does
not increase the risk of breast cancer recurrence. Patients
who undergo reoperation for bleeding are unlikely to need
more aggressive adjuvant therapy. Breast cancer surgery
involves a soft tissue surface and is often characterized by
extensive dissection, which increases the risk of postopera-
tive bleeding; the results may therefore be relevant to other
soft tissue surgical procedures.
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